Application of higenamine in prevention and treatment of Alzheimer's disease

Abstract

The invention discloses application of higenamine in prevention and treatment of Alzheimer's disease, and relates to the field of small molecule drugs in clinical medicine. The invention relates to the application of higenamine obtained through preclinical study of natural small molecule compounds inhibiting beta-amyloid polypeptide mediated [alpha]1-adrenergic receptor chronic activation cerebrovascular function change, Alzheimer's disease sample pathology change and preclinical research of cognitive impairment in prevention and treatment of Alzheimer's disease; the application or combined application of higenamine in inhibition of beta-amyloid polypeptide mediated [alpha]1-adrenergic receptor chronic activation cerebrovascular smooth muscle cell molecular signal pathway and cerebrovascular tissue activity, and improvement of cerebrovascular function changes, and Alzheimer's disease-like molecule pathology damage and behavioral disorders in Alzheimer's disease model mice is proved from molecule, cell and animal levels .

Description

technical field [0001] The invention relates to the field of clinical medicine small molecule drugs, in particular to the application of higenamine in the prevention and treatment of Alzheimer's disease. Background technique [0002] As we all know, Alzheimer's Disease (AD), also known as senile dementia, is a progressive degenerative disease of the central nervous system, mainly manifested in patients with progressive memory impairment, cognitive impairment, and language impairment. , personality loss of control and other behavioral symptoms, commonly known as "old children" and "living dead", seriously affect the life and social functions of patients, and seriously affect the quality of life of patients and close relatives. The etiology and pathogenesis of AD are not yet clear, and the characteristic pathological changes are Extracellular senile plaques by β-amyloid deposition and intracellular neurofibrillary tangles and neuronal loss by hyperphosphorylation of tau protei...

AI Technical Summary

Problems solved by technology

[0003] At present, the first-line clinical treatment drugs for AD mainly include cholinesterase inhibitors and NMDA receptor blockers, but the clinical efficacy is limited, and it is impossible to fundamentally delay, block and reverse the pathological process of AD. With the research on the pathological mechanism of AD With the continuous deepening of the research and development of new anti-AD drugs, the direction of research and development of new anti-AD drugs is gradually shifting to β-amyloid protein and tau protein. The research and development of AD treatment drugs for the pathological mechanism of AD has fallen into a bottleneck. Ascertaining the new mechanism of AD occurrence and development and finding new targets for treatment have become one of the hot spots in the research and development of new AD drugs

[0004] At present, the pathological features of AD can be summarized as β-amyloid (Aβ)-related pathological changes, tau protein-related pathological changes and progressive loss of neurons (Neuron loss), that is, the ATN system, but this system ignores the development of AD A very critical early pathological change in the process, that is, cerebrovascular lesions, has been observed in both AD patients and transgenic AD model animals. It is earlier than typical AD pathology such as senile plaques and neurofibrillary tangles, so more and more scholars have begun to put forward a new view on the occurrence and development of AD, that is, chronic cerebral palsy caused by various factors including Aβ, cholesterol, and stress hormones. Vascular lesions cause insufficient blood supply and oxygen supply to the brain, and eventually lead to progressive loss of neurons, which may be the trigger and driving factor of the pathological process of AD. Drugs can reverse early vascular lesions and improve brain blood supply, which may pave the way for the future. Prevention and treatment of AD provide new ideas